CPHI

8-K 1 cphi8k033017.htm

United States

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): March 31, 2017

CHINA PHARMA HOLDINGS,

INC.

(Exact name of Registrant as specified in charter)

Nevada 001-34471 73-1564807

(State or other jurisdiction (Commission File No.) (IRS Employer

of Incorporation)

Identification No.)

Second Floor, No. 17, Jinpan Road

Haikou, Hainan Province, China 570216

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: +86 898-6681-1730 (China)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

[ ] Written communications pursuant to Rule 425 under the Securities Act (17CFR230.425)

[ ] Soliciting material pursuant to Rule14a-12 under the Exchange Act (17CFR240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17CFR240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17CFR240.13e-4(c))

Item 2.02.Results of Operations and Financial Condition.

On March 31, 2017, the registrant issued a press release announcing (i) certain financial results for the fiscal year ended December 31, 2016; and (ii) a conference call to be held by the registrant on Friday, March 31, 2017 at 8:30 a.m. Eastern Time to discuss the results of operations for the fiscal year ended December 31, 2016. A copy of the press release is attached hereto as Exhibit 99.1.

Item 9.01.Financial Statements and Exhibits.

(d)        Exhibits.

The following is filed as an exhibit to this report:

Exhibit No.

Description

99.1

Press Release, dated March 31, 2017

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 31, 2017

CHINA PHARMA HOLDINGS, INC.

By: /s/ Zhilin Li __________________________

Name: Zhilin Li

Title: President and Chief Executive Officer

8-K 1 cph8k022508.txt

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 25, 2008

CHINA PHARMA HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware 000-29523 73-1564807 (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification Number)

2nd Floor, No. 17, Jinpan Road, Haikou, Hainan Province, China, (Address of principal executive offices)

0086-898-66811730 (China)

(Registrant's telephone number, including area code)

Not applicable (Former Name or Former Address if changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17

CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) [ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) [ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

-2-

Section 2-Financial Information

Item 2.02 Results of Operations and Financial Condition.

On February 25, 2008, China Pharma Holdings, Inc., a Delaware corporation (the "Company") issued a press release announcing, among other things, (i) new purchase orders, totaling approximately $5,600,000, from one of its main distributors, for its Pusen OK product, a generic version of Aleve-D, (ii) preliminary, unaudited, revenues for the Company of approximately $33,000,000 for the fiscal year ending on December 31, 2007, and (iii) preliminary, unaudited, revenues of approximately $4,100,000 for its Pusen OK product for the fiscal year ending on December 31, 2007.

The press release is furnished and attached hereto as Exhibit 99.1 and is incorporated by reference.

Section 8-Other Events

Item 8.01 Other Events.

The Information set forth above in "Item 2.02 - Results of Operations and Financial Condition" is incorporated herein by reference.

The press release is furnished and attached hereto as Exhibit 99.1 and is incorporated by reference.

Section 9-Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 Press Release dated February 25, 2008

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereto duly authorized.

Date: February 28, 2008 CHINA PHARMA HOLDINGS, INC., a Delaware corporation

By: /s/ Zhilin Li

Title: Chief Executive Officer

8-K 1 cph8k090606.txt

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES AND EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): September 21, 2006

China Pharma Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware 000-29523 73-1564807

(State of Incorporation) (Commission File No.) (IRS Employer ID No.)

2nd Floor, No. 17, Jinpan Road Haikou, Hainan Province, China (Address of Principal Executive Offices)

86-898-66811730 Registrant's Telephone Number, Including Area Code:

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17

CFR.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition

China Pharma Holdings, Inc. issued a press release on September 20, 2006. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Current Report included in this Item 2.02, including the exhibit included herewith, is furnished pursuant to Item 2.02 and shall not be deemed to be filed for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section.

Item 9.01. Financial Statements and Exhibits

Exhibits

99.1 Press release issued by the Company dated September 20, 2006.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

China Pharma Holdings, Inc.

Date: September 21, 2006

/s/ Zhilin Li

Zhilin Li President and CEO